CSL Pulls Plug on Seqirus Spinoff Amid Slumping Vaccine Demand

CSL’s Seqirus Spinoff Put on Ice Just last week, we finally got around to covering CSL’s (CSLLY) planned spinoff of its vaccine business, Seqirus — an ambitious move intended to unlock value for CSL shareholders. Now? Never mind. In a classic case of “right idea, wrong timing,” CSL has indefinitely postponed the spinoff due to “market volatility,”…